{"organizations": [], "uuid": "648bdf794b5e20c7cd6ff8a6dbada3415cfe331c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-8906/social", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/big-pharmas-strategy-is-music-to-biotech-investors-ears-1525191719", "country": "US", "domain_rank": 387, "title": "Big Pharma’s Strategy Is Music to Biotech Investors’ Ears", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T20:22:00.000+03:00", "replies_count": 0, "uuid": "648bdf794b5e20c7cd6ff8a6dbada3415cfe331c"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/big-pharmas-strategy-is-music-to-biotech-investors-ears-1525191719", "ord_in_thread": 0, "title": "Big Pharma’s Strategy Is Music to Biotech Investors’ Ears", "locations": [], "entities": {"persons": [{"name": "ian read", "sentiment": "none"}, {"name": "shire", "sentiment": "none"}, {"name": "kenneth frazier", "sentiment": "none"}], "locations": [], "organizations": [{"name": "big pharma", "sentiment": "negative"}, {"name": "takeda", "sentiment": "none"}, {"name": "merck mrk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Big Pharma bosses say they are willing to invest for the long run. That means high prices for promising biotech stocks aren’t likely to fall any time soon.\nMerck CEO Kenneth Frazier said on Tuesday that the company would prefer deals that boost the company’s pipeline to a large, “transformational” deal, such as a merger of equals. Pfizer CEO Ian Read also said Tuesday that he doesn’t see an attractive large-scale deal at current prices.\n... ", "external_links": ["https://djcs-olympics.s3.amazonaws.com/custom-data-charts/custom-data-chart-wsj-0.8.34.min.js", "http://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Plus-Pemetrexed-ALIMTA-and-Platinum-Chemotherapy-Reduced-the-Risk-of-Death-by-Half-Compared-with-Chemotherapy-Alone-as-First-Line-Treatment-for-Advanced-Nonsquamous-NSCLC-in-Phase-3-KEYNOTE-189-Study/default.aspx?mod=article_inline"], "published": "2018-05-01T20:22:00.000+03:00", "crawled": "2018-05-02T01:02:57.040+03:00", "highlightTitle": ""}